Use of a second drug in the same class of GLP-1 medications, liraglutide (Victoza), was linked to a 28% reduction in ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

GLP-1 drugs have been linked to numerous potential health benefits like treatment of existing conditions including heart ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.